中华皮肤科杂志 ›› 2026, e20250706.doi: 10.35541/cjd.20250706
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会
收稿日期:2025-12-16
修回日期:2026-09-10
发布日期:2026-11-06
通讯作者:
徐金华;张理涛;郝飞
E-mail:xjhhsyy@163.com; zhanglitao@medmail.com.cn; haofei62@126.com
基金资助:Chinese Society of Dermatology; China Dermatologist Association
Received:2025-12-16
Revised:2026-09-10
Published:2026-11-06
Contact:
Xu Jinhua; Zhang Litao; Hao Fei
E-mail:xjhhsyy@163.com; zhanglitao@medmail.com.cn; haofei62@126.com
Supported by:摘要: 【摘要】 血管性水肿是一种由血管通透性增加引起的,以局部皮肤和/或黏膜组织肿胀为特征的疾病,该疾病分型多,部分亚型罕见,临床漏诊或误诊率高。中华医学会皮肤性病学分会和中国医师协会皮肤科医师分会集合31位多学科专家,组建了共识专家组,基于循证医学证据及临床实践经验,提出规范的管理治疗策略。同时,本共识强调患者教育与多学科协作的重要性,以期加深临床医生对血管性水肿的认识以及提升规范化诊疗水平,共同提高血管性水肿患者的生活质量。
中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会. [开放获取] 血管性水肿诊疗中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026,e20250706. doi:10.35541/cjd.20250706
Chinese Society of Dermatology, China Dermatologist Association. Chinese expert consensus on the diagnosis and treatment of angioedema (2026 edition)[J]. Chinese Journal of Dermatology,2026,e20250706. doi:10.35541/cjd.20250706
| [1] | Maurer M, Magerl M, Betschel S, et al. The International WAO/EAACI guideline for the management of hereditary angioedema⁃the 2021 revision and update[J]. Allergy, 2022,77(7):1961⁃1990. DOI: 10.1111/all.15214. |
| [2] | 国家卫生健康委员会. 关于公布第一批罕见病目录的通知[EB/OL]. (2018⁃05⁃11)[2026⁃07⁃07]. http://www.nhc.gov.cn/yzygj/s7659/201806/393a9a37f39c4b458d6e830f40a4bb99.shtml. |
| [3] | Madsen F, Attermann J, Linneberg A. Epidemiology of non⁃hereditary angioedema[J]. Acta Derm Venereol, 2012,92(5):475⁃479. DOI: 10.2340/00015555⁃1389. |
| [4] | Sánchez⁃Borges M, Ansotegui IJ, Baiardini I, et al. The challenges of chronic urticaria part 1: epidemiology, immunopathogenesis, comorbidities, quality of life, and management[J]. World Allergy Organ J, 2021,14(6):100533. DOI: 10.1016/j.waojou.2021.100533. |
| [5] | Li J, Mao D, Liu S, et al. Epidemiology of urticaria in China: a population⁃based study[J]. Chin Med J (Engl), 2022,135(11):1369⁃1375. DOI: 10.1097/CM9.0000000000002172. |
| [6] | Ng JY, Ooi M, Bennett SK, et al. Acquired angioedema associated with lymphoproliferative disorders[J]. Case Rep Oncol, 2024,17(1):329⁃336. DOI: 10.1159/000536458. |
| [7] | Garcia⁃Saucedo JC, Trejo⁃Gutierrez JF, Volcheck GW, et al. Incidence and risk factors of angiotensin⁃converting enzyme inhibitor⁃induced angioedema: a large case⁃control study[J]. Ann Allergy Asthma Immunol, 2021,127(5):591⁃592. DOI: 10. 1016/j.anai.2021.07.028. |
| [8] | Guan X, Sheng Y, Liu S, et al. Epidemiology, economic, and humanistic burden of hereditary angioedema: a systematic review[J]. Orphanet J Rare Dis, 2024,19(1):256. DOI: 10.1186/s13023⁃024⁃03265⁃z. |
| [9] | Reshef A, Buttgereit T, Betschel SD, et al. Definition, acronyms, nomenclature, and classification of angioedema (DANCE): AAAAI, ACAAI, ACARE, and APAAACI DANCE consensus[J]. J Allergy Clin Immunol, 2024,154(2):398⁃411. DOI: 10. 1016/j.jaci.2024.03.024. |
| [10] | Lang DM, Sheikh J, Joshi S, et al. Endotypes, phenotypes, and biomarkers in chronic spontaneous urticaria: evolving toward personalized medicine[J]. Ann Allergy Asthma Immunol, 2025,134(4):408⁃417. DOI: 10.1016/j.anai.2024.10.026. |
| [11] | Puxeddu I, Pistone F, Pisani F, et al. Mast cell signaling and its role in urticaria[J]. Ann Allergy Asthma Immunol, 2024,133(4):374⁃379. DOI: 10.1016/j.anai.2024.04.023. |
| [12] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2022版)[J]. 中华皮肤科杂志, 2022,55(12):1041⁃1049. DOI: 10.35541/cjd.20220609. |
| [13] | 谢苗苗, 朱小飞. 慢性自发性荨麻疹发病机制的研究进展[J]. 免疫学杂志, 2023, 39(4):354⁃360. |
| [14] | Betschel S, Badiou J, Binkley K, et al. The International/Canadian hereditary angioedema guideline[J]. Allergy Asthma Clin Immunol, 2019,15:72. DOI: 10.1186/s13223⁃019⁃0376⁃8. |
| [15] | Sharma J, Jindal AK, Banday AZ, et al. Pathophysiology of hereditary angioedema (HAE) beyond the SERPING1 gene[J]. Clin Rev Allergy Immunol, 2021,60(3):305⁃315. DOI: 10.1007/s12016⁃021⁃08835⁃8. |
| [16] | Zuraw BL, Bork K, Bouillet L, et al. Hereditary angioedema with normal C1 inhibitor: an updated international consensus paper on diagnosis, pathophysiology, and treatment[J]. Clin Rev Allergy Immunol, 2025,68(1):24. DOI: 10.1007/s12016⁃025⁃09027⁃4. |
| [17] | Castelli R, Zanichelli A, Cicardi M, et al. Acquired C1⁃inhibitor deficiency and lymphoproliferative disorders: a tight relationship[J]. Crit Rev Oncol Hematol, 2013,87(3):323⁃332. DOI: 10. 1016/j.critrevonc.2013.02.004. |
| [18] | Lacuesta G, Betschel SD, Tsai E, et al. Angioedema[J]. Allergy Asthma Clin Immunol, 2024,20(Suppl 3):65. DOI: 10.1186/s13223⁃024⁃00934⁃3. |
| [19] | Mathey CM, Maj C, Scheer AB, et al. Molecular genetic screening in patients with ACE inhibitor/angiotensin receptor blocker⁃induced angioedema to explore the role of hereditary angioedema genes[J]. Front Genet, 2022,13:914376. DOI: 10. 3389/fgene.2022.914376. |
| [20] | Maurer M, Magerl M. Differences and similarities in the mechanisms and clinical expression of bradykinin⁃mediated vs. mast cell⁃mediated angioedema[J]. Clin Rev Allergy Immunol, 2021,61(1):40⁃49. DOI: 10.1007/s12016⁃021⁃08841⁃w. |
| [21] | Balla Z, Andrási N, Pólai Z, et al. The characteristics of upper airway edema in hereditary and acquired angioedema with C1⁃inhibitor deficiency[J]. Clin Transl Allergy, 2021,11(10):e12083. DOI: 10.1002/clt2.12083. |
| [22] | Obtułowicz P, Stobiecki M, Dyga W, et al. Abdominal and pelvic imaging in the diagnosis of acute abdominal attacks in patients with hereditary angioedema due to C1⁃inhibitor deficiency[J]. Postepy Dermatol Alergol, 2022,39(4):749⁃756. DOI: 10.5114/ada.2021.108438. |
| [23] | Caballero T, Maurer M, Longhurst HJ, et al. Triggers and prodromal symptoms of angioedema attacks in patients with hereditary angioedema[J]. J Investig Allergol Clin Immunol, 2016,26(6):383⁃386. DOI: 10.18176/jiaci.0102. |
| [24] | Maia L, Moreno AS, Ferriani M, et al. Genotype⁃phenotype correlations in Brazilian patients with hereditary angioedema due to C1 inhibitor deficiency[J]. Allergy, 2019,74(5):1013⁃1016. DOI: 10.1111/all.13699. |
| [25] | Montinaro V, Cicardi M. ACE inhibitor⁃mediated angioedema[J]. Int Immunopharmacol, 2020,78:106081. DOI: 10.1016/j.intimp.2019.106081. |
| [26] | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南(2018版)[J]. 中华皮肤科杂志, 2019,52(1):1⁃5. DOI: 10.3760/cma.j.issn.0412⁃4030.2019.01.001. |
| [27] | Tarzi MD, Hickey A, Förster T, et al. An evaluation of tests used for the diagnosis and monitoring of C1 inhibitor deficiency: normal serum C4 does not exclude hereditary angioedema[J]. Clin Exp Immunol, 2007,149(3):513⁃516. DOI: 10.1111/j.1365⁃2249.2007.03438.x. |
| [28] | Busse PJ, Christiansen SC, Riedl MA, et al. US HAEA medical advisory board 2020 guidelines for the management of hereditary angioedema[J]. J Allergy Clin Immunol Pract, 2021,9(1):132⁃150.e3. DOI: 10.1016/j.jaip.2020.08.046. |
| [29] | Zanichelli A, Arcoleo F, Barca MP, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy[J]. Orphanet J Rare Dis, 2015,10:11. DOI: 10.1186/s13023⁃015⁃0233⁃x. |
| [30] | Gil⁃Serrano J, Labrador⁃Horrillo M, Galvan⁃Blasco P, et al. Systemic inflammation biomarkers during angioedema attacks in hereditary angioedema[J]. Front Immunol, 2024,15:1400526. DOI: 10.3389/fimmu.2024.1400526. |
| [31] | 遗传性血管性水肿消化科诊疗协作组. 遗传性血管性水肿消化科诊疗路径[J]. 中华消化杂志, 2024,44(5):289⁃295. DOI: 10.3760/cma.j.cn311367⁃20240229⁃00078. |
| [32] | 周宁, 韩小彤, 陈松, 等. 遗传性血管性水肿急诊科诊疗路径[J]. 中国急救医学, 2024,44(2):99⁃105. DOI: 10.3969/j.issn. 1002⁃1949.2024.02.002. |
| [33] | Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA²LEN/Euroguiderm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria[J]. Allergy, 2022,77(3):734⁃766. DOI: 10.1111/all. 15090. |
| [34] | Can PK, Degi Rmentepe EN, Etikan P, et al. Assessment of disease activity and quality of life in patients with recurrent bradykinin⁃mediated versus mast cell⁃mediated angioedema[J]. World Allergy Organ J, 2021,14(7):100554. DOI: 10.1016/j.waojou.2021.100554. |
| [35] | Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test (AECT)⁃a patient⁃reported outcome instrument for assessing angioedema control[J]. J Allergy Clin Immunol Pract, 2020,8(6):2050⁃2057.e4. DOI: 10.1016/j.jaip. 2020.02.038. |
| [36] | Mak H, Wong J, So S, et al. Validation and correlations of the Angioedema Activity Score (AAS), Angioedema Quality of Life (AE⁃QoL) questionnaire, and Angioedema Control Test (AECT) in Chinese patients with angioedema[J]. J Allergy Clin Immunol Glob, 2024,3(4):100295. DOI: 10.1016/j.jacig.2024. 100295. |
| [37] | Chaichan W, Ruengorn C, Thavorn K, et al. Comparative safety profiles of individual second⁃generation H1⁃antihistamines for the treatment of chronic urticaria: a systematic review and network meta⁃analysis of randomized controlled trials[J]. J Allergy Clin Immunol Pract, 2023,11(8):2365⁃2381. DOI: 10. 1016/j.jaip.2023.03.058. |
| [38] | Zhang L, Wu J, Qi Y, et al. Long⁃term combinations and updosing of second⁃generation H1⁃antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: a multicenter real⁃life pilot study[J]. J Allergy Clin Immunol Pract, 2020,8(5):1733⁃1736. DOI: 10.1016/j.jaip.2019. 12.006. |
| [39] | Iriarte Sotés P, Armisén M, Usero⁃Bárcena T, et al. Efficacy and safety of up⁃dosing antihistamines in chronic spontaneous urticaria: a systematic review of the literature[J]. J Investig Allergol Clin Immunol, 2021,31(4):282⁃291. DOI: 10.18176/jiaci.0649. |
| [40] | Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials[J]. J Allergy Clin Immunol, 2016,137(6):1742⁃1750. DOI: 10.1016/j.jaci.2015.12.1342. |
| [41] | Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review[J]. J Allergy Clin Immunol Pract, 2018,6(2):586⁃599. DOI: 10.1016/j.jaip.2017.07.017. |
| [42] | Hide M, Staubach P, Khemis A, et al. Remibrutinib demonstrates sustained control of angioedema in patients with chronic spontaneous urticaria: 52⁃week treatment results from the phase 3 REMIX studies[C]//EAACI 2025, 2025. |
| [43] | Ding L, Zhang MJ, Rao GW. Summary and future of medicine for hereditary angioedema[J]. Drug Discov Today, 2024,29(3):103890. DOI: 10.1016/j.drudis.2024.103890. |
| [44] | Nicola S, Rolla G, Brussino L. Breakthroughs in hereditary angioedema management: a systematic review of approved drugs and those under research[J]. Drugs Context, 2019,8:212605. DOI: 10.7573/dic.212605. |
| [45] | Uminski K, Goodyear D, Betschel S. Therapeutic advances in hereditary angioedema: a focus on present and future options[J]. Adv Ther, 2025,42(12):5879⁃5895. DOI: 10.1007/s12325⁃025⁃03382⁃6. |
| [46] | Craig TJ, Bewtra AK, Bahna SL, et al. C1 esterase inhibitor concentrate in 1085 hereditary angioedema attacks⁃⁃final results of the I.M.P.A.C.T.2 study[J]. Allergy, 2011,66(12):1604⁃1611. DOI: 10.1111/j.1398⁃9995.2011.02702.x. |
| [47] | Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1⁃inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema[J]. J Allergy Clin Immunol, 2010,126(4):821⁃827. DOI: 10.1016/j.jaci.2010.07.021. |
| [48] | Rosi⁃Schumacher M, Shah SJ, Craig T, et al. Clinical manifestations of hereditary angioedema and a systematic review of treatment options[J]. Laryngoscope Investig Otolaryngol, 2021,6(3):394⁃403. DOI: 10.1002/lio2.555. |
| [49] | Wentzel N, Panieri A, Ayazi M, et al. Fresh frozen plasma for on⁃demand hereditary angioedema treatment in south africa and iran[J]. World Allergy Organ J, 2019,12(9):100049. DOI: 10.1016/j.waojou.2019.100049. |
| [50] | Farkas H, Zotter Z, Csuka D, et al. Short⁃term prophylaxis in hereditary angioedema due to deficiency of the C1⁃inhibitor⁃⁃a long⁃term survey[J]. Allergy, 2012,67(12):1586⁃1593. DOI: 10.1111/all.12032. |
| [51] | 中国医师协会变态反应医师分会, 中华医学会变态反应学分会, 中国罕见病联盟北京罕见病诊疗与保障学会变态反应学分会, 等. 中国遗传性血管性水肿诊断与治疗专家共识(2024版)[J]. 中华临床免疫和变态反应杂志, 2025,19(1):1⁃10. DOI: 10.3969/j.issn.1673⁃8705.2025.01.001. |
| [52] | Prematta M, Gibbs JG, Pratt EL, et al. Fresh frozen plasma for the treatment of hereditary angioedema[J]. Ann Allergy Asthma Immunol, 2007,98(4):383⁃388. DOI: 10.1016/S1081⁃1206(10)60886⁃1. |
| [53] | Beard N, Frese M, Smertina E, et al. Interventions for the long⁃term prevention of hereditary angioedema attacks[J]. Cochrane Database Syst Rev, 2022,11:CD013403. DOI: 10.1002/14651858. CD013403.pub2. |
| [54] | Betschel S, Badiou J, Binkley K, et al. Correction to: the International/Canadian hereditary angioedema guideline[J]. Allergy Asthma Clin Immunol, 2020,16:33. DOI: 10.1186/s13223⁃ 020⁃00430⁃4. |
| [55] | Xu Y, Zhi Y. Long⁃term prophylaxis of hereditary angioedema with danazol[J]. Chin Med J (Engl), 2022,135(21):2642⁃2643. DOI: 10.1097/CM9.0000000000002144. |
| [56] | Horiuchi T, Hide M, Yamashita K, et al. The use of tranexamic acid for on⁃demand and prophylactic treatment of hereditary angioedema: a systematic review[J]. J Cutan Immunol Allergy, 2018,1:126⁃138. DOI: 10.1002/cia2.12029. |
| [57] | Zingale LC, Castelli R, Zanichelli A, et al. Acquired deficiency of the inhibitor of the first complement component: presentation, diagnosis, course, and conventional management[J]. Immunol Allergy Clin North Am, 2006,26(4):669⁃690. DOI: 10.1016/j.iac.2006.08.002. |
| [58] | Longhurst HJ, Zanichelli A, Caballero T, et al. Comparing acquired angioedema with hereditary angioedema (types i/ii): findings from the icatibant outcome survey[J]. Clin Exp Immunol, 2017,188(1):148⁃153. DOI: 10.1111/cei.12910. |
| [59] | Xiao X, Xue P, Shi Y, et al. The efficacy and safety of high⁃dose nonsedating antihistamines in chronic spontaneous urticaria: a systematic review and meta⁃analysis of randomized clinical trials[J]. BMC Pharmacol Toxicol, 2023,24(1):23. DOI: 10.1186/s40360⁃023⁃00665⁃y. |
| [60] | Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study[J]. Allergy, 2021,76(4):1271⁃1273. DOI: 10.1111/all.14686. |
| [61] | Nettis E, Cegolon L, Di Leo E, et al. Omalizumab in elderly patients with chronic spontaneous urticaria: an Italian real⁃life experience[J]. Ann Allergy Asthma Immunol, 2018,120(3):318⁃323. DOI: 10.1016/j.anai.2017.12.007. |
| [62] | Levi⁃Schaffer F, Mankuta D. Omalizumab safety in pregnancy[J]. J Allergy Clin Immunol, 2020,145(2):481⁃483. DOI: 10. 1016/j.jaci.2019.11.018. |
| [63] | González⁃Quevedo T, Larco JI, Marcos C, et al. Management of pregnancy and delivery in patients with hereditary angioedema due to C1 inhibitor deficiency[J]. J Investig Allergol Clin Immunol, 2016,26(3):161⁃167. DOI: 10.18176/jiaci.0037. |
| [64] | Norris M, Ashoor Z, Craig T. Management of pediatric hereditary angioedema types 1 and 2: a search for international consensus[J]. Allergy Asthma Proc, 2022,43(5):388⁃396. DOI: 10.2500/aap.2022.43.220052. |
| [65] | 贾薇, 索利敏, 范林静, 等. 一个遗传性血管性水肿家系的临床及基因研究[J]. 中华耳鼻咽喉头颈外科杂志, 2022,57(8):980⁃985. DOI: 10.3760/cma.j.cn115330⁃20211209⁃00789. |
| [1] | 中国医师协会皮肤科医师分会 中华医学会皮肤性病学分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤病学分会 . [开放获取] 斑块状银屑病生物制剂长程治疗管理专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(9): 827-843. |
| [2] | 高海清 马莉 杨凡萍 陈圣安 赵颖 骆肖群. 36例遗传性血管性水肿患者临床及遗传特征分析[J]. 中华皮肤科杂志, 2026, 59(9): 881-887. |
| [3] | 《西罗莫司治疗卡波西样血管内皮瘤中国专家共识(版)》制订专家组. 西罗莫司治疗卡波西样血管内皮瘤中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(8): 728-737. |
| [4] | 《脓疱型银屑病诊疗中国专家共识(版)》编写委员会专家组. [开放获取] 脓疱型银屑病诊疗中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(8): 717-727. |
| [5] | 陈荃 何凤梅 周欣 梁碧华 朱慧兰. 日光性荨麻疹:机制研究和治疗现状与展望[J]. 中华皮肤科杂志, 2026, 59(7): 619-625. |
| [6] | 中国“一带一路”皮肤病学专科联盟水疱病专病联盟 中华医学会皮肤性病学分会天疱疮/大疱性类天疱疮研究协作组. 抗p200类天疱疮诊断与治疗专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(5): 387-395. |
| [7] | 中国妇幼保健协会儿童变态反应专业委员会儿童皮肤病学组. 儿童肛门生殖器硬化性苔藓诊疗管理中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(5): 396-406. |
| [8] | 中国康复医学会皮肤病康复专业委员会毛发疾病康复学组 北京整合医学学会毛发医学分会 中华医学会皮肤性病学分会毛发学组 国家皮肤与免疫疾病临床医学研究中心. 毛发活检病理中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(5): 419-426. |
| [9] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤病学分会. [开放获取] 肠道菌群移植治疗银屑病专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(5): 427-435. |
| [10] | 中国整形美容协会皮肤美容分会 中国非公立医疗机构协会皮肤专业委员会. [开放获取] 医用重组人源化胶原蛋白在面部年轻化中的应用专家建议(2026版)[J]. 中华皮肤科杂志, 2026, 59(4): 320-326. |
| [11] | 中华医学会皮肤性病学分会儿童学组 中国康复医学会皮肤病康复专业委员会儿童皮肤病学组 中国医师协会皮肤科医师分会儿童皮肤病学组 中国中药协会儿童健康与药物研究专业委员会外治疗法学组 中国医师协会儿科分会皮肤病学组 . 中国儿童斑秃诊断和治疗专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(4): 291-303. |
| [12] | 中国医学装备协会皮肤病与皮肤美容分会 中国临床肿瘤学会患者教育专家委员会. [开放获取] 肿瘤治疗相关皮肤不良反应多学科管理中国专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(4): 304-319. |
| [13] | 中华医学会皮肤性病学分会银屑病专业委员会. 伴共病的银屑病管理共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(3): 193-207. |
| [14] | “Chinese expert consensus on the clinical application of photobiomodulation therapy in dermatology ”解读专家组 中华医学会皮肤性病学分会激光学组. [开放获取] 2025版光生物调节疗法在皮肤科的临床应用中国专家共识要点解读[J]. 中华皮肤科杂志, 2026, 59(3): 208-212. |
| [15] | 中华医学会皮肤性病学分会 中国医师协会皮肤科医师分会 中国医疗保健国际交流促进会皮肤医学分会 中国罕见病联盟皮肤罕见病专业委员会. [开放获取] 佩索利单抗治疗炎症性皮肤病专家共识(2026版)[J]. 中华皮肤科杂志, 2026, 59(2): 113-119. |
|